Track Seer, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Seer, Inc. SEER · Stock Open Seer, Inc. in new tab

2.24 USD
EPS
-1.24
P/B
0.51
ROE
-25.52
Beta
1.60
Loading chart...
Key Metrics
Earnings dateAug. 5, 2026
EPS-1.24
Book Value4.39
Price to Book0.51
Debt/Equity9.54
% Insiders14.368%
Growth
Revenue Growth-0.34%
Estimates
Forward P/E-2.27
Forward EPS-0.98

DCF Valuation

Tweak assumptions to recompute fair value for Seer, Inc. (SEER)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Seer, Inc. Logo Seer, Inc. Analysis (SEER)

United States Health Care Official Website Stock

Is Seer, Inc. a good investment? Seer, Inc. (SEER) is currently trading at 2.24 USD.

Earnings Schedule: Seer, Inc. is expected to release its next earnings report on Aug. 5, 2026. The market consensus estimate for Forward EPS is -0.98.

Investor FAQ

Does Seer, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Seer, Inc.?

Seer, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Aug. 5, 2026. The company currently has a trailing EPS of -1.24.

Company Profile

Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company also offers Proteograph ONE, a third-generation assay; Proteograph DIRECT, which provides an automated approach for direct digestion of samples for bottom-up LC-MS proteomic analysis; and Proteograph Analysis Suite, a data analytics software suite designed to support quality control, data management, and interpretation of Proteograph output which is currently offered as a cloud-based solution. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

Exchange Ticker
NMS (United States) SEER
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion